نتایج جستجو برای: hiv vaccine

تعداد نتایج: 309384  

Journal: :Vaccine 2004
C Jane Dale Robert De Rose Kim M Wilson Hayley A Croom Scott Thomson Barbara E H Coupar Alistair Ramsay Damian F J Purcell Rosemary Ffrench Matthew Law Sean Emery David A Cooper Ian A Ramshaw David B Boyle Stephen J Kent

Induction of HIV-specific T-cell responses by vaccines may facilitate efficient control of HIV. Plasmid DNA vaccines and recombinant fowlpoxvirus (rFPV) vaccines are promising HIV-1 vaccine candidates, although either vaccine alone may be insufficient to protect against HIV-1. A consecutive immunisation strategy involving priming with DNA and boosting with rFPV vaccines encoding multiple common...

Journal: :iranian journal of immunology 0
fatemeh roodbari department of virology, faculty of medical sciences, tarbiat modares university, tehran farzaneh sabahi department of virology, faculty of medical sciences, tarbiat modares university, tehran mohamad nabi sarbolouki institute of biochemistry and biophysics, tehran university of basic sciences farzaneh barkhordari biotechnology research center, pasteur institute of iran, tehran ahmad adeli biotechnology research center, pasteur institute of iran, tehran amel jamedar department of virology, faculty of medical sciences, tarbiat modares university, tehran fereidoun mahboudi

background: development of an effective vaccine is highly needed in order to restrict the aids pandemic. dna vaccines initiate both arms of immunity without the potential of causing disease. hiv-1 p24 and gp41 (gag and env) proteins play important roles in viral pathogenesis and are effective candidates for immune induction and vaccine design. objective: in this study, new dna vaccine candidate...

2018
Byoung-Jun Kim Bo-Ram Kim Yoon-Hoh Kook Bum-Joon Kim

Citation: Kim B-J, Kim B-R, Kook Y-H and Kim B-J (2018) Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine. Front. Immunol. 9:643. doi: 10.3389/fimmu.2018.00643 Development of a live recombinant Bcg expressing human immunodeficiency Virus Type 1 (hiV-1) gag Using a pMyong2 Vector ...

Journal: :The Journal of infectious diseases 1994
J R Mascola J Louwagie F E McCutchan C L Fischer P A Hegerich K F Wagner A K Fowler J G McNeil D S Burke

At least five distinct genetic subtypes (genotypes) of human immunodeficiency virus type 1 (HIV-1) have been identified by DNA sequencing. Current vaccine candidates are based on virus strains from North America and Europe that represent only one subtype. The extent to which distinct genotypes of HIV-1 correspond to antigenically distinguishable serotypes is largely unknown and may be criticall...

Journal: :PLoS Medicine 2006
Robert Hecht Chutima Suraratdecha

A t the end of 2005, about 40 million people worldwide were living with HIV/AIDS, most of them adults and 95 percent of them living in developing countries. Although vigorous prevention programs are under way in many countries, about 3 million people still died from AIDS in 2005 and more than 13,000 people became infected with HIV every day [1]. Hence there is an urgent need for stronger and mo...

2010
Rui Gu Anae Shampang Toufic Nashar Manisha Patil Deborah H. Fuller Arlene I. Ramsingh

BACKGROUND The development of an HIV/AIDS vaccine has proven to be elusive. Because human vaccine trials have not yet demonstrated efficacy, new vaccine strategies are needed for the HIV vaccine pipeline. We have been developing a new HIV vaccine platform using a live enterovirus, coxsackievirus B4 (CVB4) vector. Enteroviruses are ideal candidates for development as a vaccine vector for oral de...

2009

Objective 1: Define the safety and efficacy of the multiclade DNA prime/rAd5 boost VRC candidate HIV-1 vaccine. Objective 2: Define immunological correlates of vaccine-induced protection from HIV-1 acquisition and/or disease progression to advance development of an HIV-1 candidate Objective 1: Determine the structure of a trimeric HIV-1 Envelope spike and delineate how oligomerization influence...

Journal: :Vaccine 2005
Scott A Thomson Angel B Jaramillo Maryanne Shoobridge Kerrie J Dunstan Beth Everett Charani Ranasinghe Stephen J Kent Ke Gao Jill Medveckzy Rosemary A Ffrench Ian A Ramshaw

Induction of high levels of broadly reactive cytotoxic T lymphocytes (CTL) remains a promising approach for an effective HIV-1 vaccine. We have developed a novel genetic-based vaccine strategy that encodes consensus overlapping peptide sets from all HIV-1 proteins scrambled together. This synthetic scrambled antigen vaccine (SAVINE) strategy has significant advantages, e.g. capacity to encode m...

2015
Zoe Moodie Barbara Metch Linda-Gail Bekker Gavin Churchyard Maphoshane Nchabeleng Koleka Mlisana Fatima Laher Surita Roux Kathryn Mngadi Craig Innes Matsontso Mathebula Mary Allen Carter Bentley Peter B. Gilbert Michael Robertson James Kublin Lawrence Corey Glenda E. Gray Alan Landay

BACKGROUND The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and efficacy of the MRK Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine vs placebo in sexually active HIV-1 seronegative participants in South Africa. Enrollment and vaccinations stopped and participants were unblinded but continued follow-up when the Step study evaluating the same vaccine in the Amer...

2017
Selma Bekri Pierre Bourdely Carmelo Luci Nathalie Dereuddre-Bosquet Bin Su Frédéric Martinon Véronique M. Braud Irene Luque Pedro L. Mateo Sara Crespillo Francisco Conejero-Lara Christiane Moog Roger Le Grand Fabienne Anjuère

Persistent B cell responses in mucosal tissues are crucial to control infection against sexually transmitted pathogens like human immunodeficiency virus 1 (HIV-1). The genital tract is a major site of infection by HIV. Sublingual (SL) immunization in mice was previously shown to generate HIV-specific B cell immunity that disseminates to the genital tract. We report here the immunogenicity in fe...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید